Trial Profile
A randomized multicenter trial comparing weekly docetaxel and CMF [cyclophosphamide + methotrexate + fluorouracil] in the adjuvant treatment of women with high-risk breast cancer who are greater than 65 years old or are not candidates for anthracycline-based adjuvant therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Fluorouracil; Methotrexate
- Indications Breast cancer
- Focus Therapeutic Use
- 17 Aug 2008 Planned end date added (1 Dec 2009) as reported by ClinicalTrials.gov.
- 27 Nov 2005 New trial record.